UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008017
Receipt number R000009431
Scientific Title Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
Date of disclosure of the study information 2012/05/23
Last modified on 2020/11/30 12:33:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>

Acronym

Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>

Scientific Title

Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>

Scientific Title:Acronym

Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>

Region

Japan


Condition

Condition

follicular lymphoma

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma[FL]

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival at 2 years[2y PFS]

Key secondary outcomes

Best Response Rate, Complete Response Rate, Overall Response Rate, Overall survival, Progression Free Survival, Bcl-2 negative conversion rate, Minimal Residual Disease, Safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rituximab combination chemotherapy 1course/3W [Maximum 6-8 course]

Rituximab monotherapy 1course/8W[until 2 years]
Rituximab 375 mg/m2 div day0 or day1

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1)Follicular lymphoma[FL]
[exclude patients with Histologic transformation]
2)grade 1, 2, 3a
3)no previous chemotherapy
4)CD20 positive
5)Age:18 to 74
6)Performance Status:0 to 2
7)having musurable lesion
8-1)WBC:3,000/mm3 or more
Neutrophil:1,200/mm3 or more
Platlets:7.5x10^4/mm3 or more
8-2)AST[GOT]/ALT[GPT]:5xnormal upper
limit or less
T-bil:2.0mg/dL or less
8-3)Creatinine:1.5mg/dL or less
9)Written informed consen

Key exclusion criteria

1)active double cancer
2)severe infection or severe complication
3)having prior drug allergy
4)prior treated heart failure or renal failure
5)Cirrhosis of the liver
6)HBs-Ag positive
7)Disorder of electrocardiogram, Disorder of heart fanction, severe heart disease
8)pregnant/lactating woman
9)psychosis
10)given systemic steroid
11)Physician's decision of inappropriateness

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Eijiro
Middle name
Last name Omoto

Organization

Yamagata Prefectural Central Hospital

Division name

Department of Hematology

Zip code

990-2292

Address

1800 Aoyagi, Yamagata city, Yamagata, 990-2292, JAPAN

TEL

023-685-2626

Email

ej-omoto@vega.ocn.ne.jp


Public contact

Name of contact person

1st name Eijiro
Middle name
Last name Omoto

Organization

Yamagata Prefectural Central Hospital

Division name

Department of Hematology

Zip code

990-2292

Address

1800 Aoyagi, Yamagata city, Yamagata, 990-2292, JAPAN

TEL

023-685-2626

Homepage URL


Email

ej-omoto@vega.ocn.ne.jp


Sponsor or person

Institute

TOHOKU HEMATOLOGY FORUM

Institute

Department

Personal name



Funding Source

Organization

Tohoku Hematology Expert Meeting (THEMe)

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

TOHOKU HEMATOLOGY FORUM

Name of secondary funder(s)



IRB Contact (For public release)

Organization

IRB of Yamagata Prefectural Central Hospital

Address

1800 Aoyagi, Yamagata City, Yamagata

Tel

0236852626

Email

eomoto@ypch.gr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 05 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

24

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2012 Year 04 Month 27 Day

Date of IRB

2012 Year 05 Month 16 Day

Anticipated trial start date

2012 Year 06 Month 01 Day

Last follow-up date

2022 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 05 Month 23 Day

Last modified on

2020 Year 11 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009431


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name